Alzheimer's Dx: An Essential Piece of the Puzzle
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.
You may also be interested in...
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
Brief summaries of recent medtech market and industry developments. This month we cover Covidien’s continuing buying spree, and other medtech M&A.
Marketplace uncertainty and pressures to reduce costs have had a major impact on the market for medical imaging technologies. Medtech Insight interviews Gregory Sorensen, MD, Siemens Healthcare’s CEO for North America about what’s on the horizon for the industry.